N

Noctrix Health

Prescription wearable neuromodulation for RLS.

Payments Associate

Full-TimeUpdated on 10/23/2026
$24 - $60k
Junior
Pleasanton, CA, USA
HybridHybrid in Pleasanton, CA; requires at least three days onsite per week.
AccountingAccounts Payable/Receivable

About the job

Requirements
  • At least one year of experience in a medical billing office, healthcare reimbursement, health insurance, revenue cycle, or a related healthcare environment.
  • Experience processing or posting medical reimbursement payments, adjustments, or related financial transactions.
  • Familiarity with medical billing systems and healthcare reimbursement workflows.
  • Experience reviewing insurance Explanation of Benefits (EOBs) and contractual adjustments.
  • Understanding of payment reconciliation and the ability to identify and resolve discrepancies.
  • Strong Microsoft Excel or spreadsheet skills.
  • High degree of accuracy in data entry and financial calculations.
  • Strong attention to detail and the ability to work accurately with high-volume financial and patient information.
  • Strong organizational and administrative skills.
  • Understanding of HIPAA and applicable healthcare privacy requirements.
  • Ability to independently prioritize and manage multiple responsibilities and deadlines.
  • Strong written and verbal communication skills.
  • Ability to collaborate effectively with Billing, Finance, Accounting, and other cross-functional stakeholders.
  • Ability to work effectively in a fast-paced, high-growth environment.
Responsibilities
  • Accurately post reimbursement payments, contractual adjustments, denials, and other payment-related transactions to patient accounts.
  • Review EOBs and other payer documentation to ensure payments, adjustments, and claim statuses are accurately recorded.
  • Reconcile daily bank deposits, ACH transactions, credit card payments, and other payment activity against billing system transaction reports.
  • Investigate and resolve misapplied payments, unapplied cash, payment discrepancies, and other reconciliation issues.
  • Process virtual payment cards and ensure transactions are accurately recorded and reconciled.
  • Organize and distribute payment checks, virtual payment information, and related documentation to Accounting and Billing team members for appropriate processing.
  • Retrieve, scan, upload, and appropriately distribute incoming payer claims correspondence and reimbursement documentation.
  • Maintain accurate patient, payment, claim, and reimbursement information within billing and patient documentation systems.
  • Generate payment and reconciliation reports for management review.
  • Partner with Finance and Accounting to investigate and resolve payment or reconciliation discrepancies.
  • Support month-end close activities by providing payment reconciliation, reporting, and supporting documentation.
  • Assist with discrepancies identified by Finance or Accounting during month-end close and reconciliation activities.
  • Maintain organized and complete documentation to support payment processing, reconciliation, and audit readiness.
  • Assist with billing compliance initiatives, regulatory inspections, audits, and related documentation requests.
  • Identify recurring payment discrepancies or process issues and escalate trends and opportunities for improvement.
  • Collaborate with Billing & Collections, Finance, Accounting, and other cross-functional stakeholders to resolve payment-related issues.
  • Handle patient and reimbursement information in accordance with HIPAA, applicable billing regulations, insurance requirements, and company policies.
  • Maintain a high degree of accuracy and productivity while managing multiple payment and administrative workflows in a fast-paced environment.
Desired Qualifications
  • Experience with NikoHealth, Brightree, or similar medical billing and revenue cycle systems.
  • Experience posting and reconciling payer reimbursement payments.
  • Experience processing virtual payment cards, ACH transactions, checks, and credit card payments.
  • Experience investigating unapplied cash, misapplied payments, and payment discrepancies.
  • Experience supporting month-end close and reconciliation activities.
  • Experience generating payment or reconciliation reports.
  • Experience supporting healthcare billing audits, regulatory inspections, or compliance activities.
  • Experience within DME, medical device, or healthcare reimbursement.
  • Experience working within a startup or rapidly growing healthcare organization.

About the company

Noctrix Health makes prescription wearable therapy for Restless Legs Syndrome using the NTX100 Tonic Motor Activation System (Nidra). It uses leg bands to stimulate the peroneal nerves at night, producing gentle muscle activation that reduces RLS sensations and improves sleep. The device is prescribed through healthcare providers for adults with moderate-to-severe, medication-refractory RLS and is backed by FDA De Novo clearance in 2023 following a Breakthrough Device Designation and a multi-center trial. The goal is to establish wearable therapeutics as a standard non-drug treatment option to improve sleep for people with RLS.

Company Size

51-200

Company Stage

Acquired

Total Funding

$90.5M

Headquarters

Pleasanton, California

Founded

2018

Get referred to Noctrix Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Noctrix reached roughly $24 million annual run-rate revenue before the June 2026 close.
  • Medicare and VA access expanded in 2024-2026, strengthening patient conversion.
  • Resmed will push Nidra through its sleep physician and HME/DME channels.

What critics are saying

  • Resmed now owns Noctrix, eliminating independent-company upside for new investors and employees.
  • Coverage remains fragmented; many insurers still require case-by-case reviews and appeals, slowing sales.
  • If Resmed deprioritizes Nidra, Noctrix disappears inside a much larger sleep portfolio.

What makes Noctrix Health unique

  • Nidra is the only FDA De Novo wearable treatment for refractory RLS since 2023.
  • AASM guidelines in 2025 endorsed bilateral peroneal nerve stimulation for RLS symptoms.
  • Resmed closed the $340 million acquisition on June 1, 2026, validating market pull.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

4%

1 year growth

3%

2 year growth

0%
Sleep Review Magazine
May 5th, 2026
Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker.

Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker. Resmed will acquire the manufacturer of an fda-cleared nerve stimulation device for refractory RLS, a move that leverages its existing sleep physician and home medical equipment channels. Key takeaways: * Resmed has signed an agreement to acquire Noctrix Health, maker of the Nidra device, for a purchase price of $340 million. * The acquisition targets the estimated 7% of adults globally affected by RLS, a population with meaningful overlap with obstructive sleep apnea. * The transaction is expected to close around June 1, 2026, with revenue to be reported within Resmed's Americas Devices category. Resmed has signed a $340 million agreement to acquire Noctrix Health, a medical device company with an FDA de novo classified product indicated for the treatment of refractory moderate-to-severe restless legs syndrome (RLS). The flagship product, Nidra, is a noninvasive nerve stimulation device. The acquisition marks Resmed's expansion into adjacent sleep health markets, targeting what is considered the third-most-prevalent sleep disorder after obstructive sleep apnea (OSA) and insomnia. RLS affects approximately 7% of adults globally, including around 17 million people in the US, and has a meaningful overlap with OSA. "RLS treatments from Noctrix are noninvasive, clinically proven, and drug-free, just like our CPAP/APAP and bilevel therapies," said Michael Farrell, CEO and chairman of the board at Resmed, during the company's third-quarter earnings call. Resmed, which has been an investor in Noctrix since 2024, plans to leverage its established market access to scale the therapy. Prescriptions for the device are written predominantly by sleep physicians and flow through the same home medical equipment (HME) and durable medical equipment (DME) delivery channels where Resmed currently holds a leading market share. "The reach of our Resmed brand among sleep physicians and HME providers as well as our national and international distribution channel strength makes us the best owner of this scarce asset," Farrell said. The transaction is targeted to close on or around June 1, 2026. Noctrix currently has an annual run rate revenue of approximately $24 million, which Resmed notes is growing at a faster rate and operating at a higher gross margin than Resmed's core business. Once closed, Noctrix's financials will be reported within Resmed's Americas Devices category. The acquisition is expected to result in an approximate $0.02 reduction in non-GAAP earnings per share for the fourth quarter of fiscal year 2026 as Resmed continues to invest in research and development and sales and marketing for the new asset.

Simply Wall St
May 1st, 2026
ResMed names new CFO and acquires Noctrix Health to expand into neurology

ResMed has appointed Aaron Bloomer as chief financial officer, replacing retiring CFO Brett Sandercock, and agreed to acquire Noctrix Health, a medical device company specialising in restless leg syndrome treatments. The moves mark a strategic shift for ResMed, which is primarily known for sleep apnoea devices and related software. The Noctrix acquisition expands the company's portfolio into neurological conditions affecting sleep quality, broadening its clinical scope beyond traditional respiratory care. Investors will be watching how ResMed balances capital allocation between its core sleep apnoea business and new neurology-related devices. Integration risks around Noctrix, including regulatory and reimbursement hurdles, remain key factors to monitor. At $213.81, ResMed shares trade approximately 26% below the analyst target of $288.21.

Michael West Media
May 1st, 2026
Snoring leader buys restless leg syndrome device maker - Michael West

Sleep apnoea company Resmed has acquired a California firm that makes a device for patients with restless leg syndrome, the third-biggest sleep disorder.

FinSMEs
Sep 2nd, 2025
Noctrix Health Raises Up To $33.5M in Debt and Equity Funding

Noctrix Health raises up to $33.5M in debt and equity funding.

FinancialContent
Aug 29th, 2025
Noctrix Health Raises $33.5M for RLS Therapy

Noctrix Health has raised $33.5 million to accelerate the U.S. commercialization of its Nidra® TOMAC therapy for Restless Legs Syndrome (RLS). The funding includes contributions from Blue Venture Fund, Sandbox Clinical Ventures, and a debt facility from Bridge Bank. The company has also expanded its leadership team, appointing Ivan Lubogo as Chief Commercial Officer and promoting Jonathan Charlesworth, Ph.D., to Chief Scientific Officer. Mark Verratti joins the Board of Directors.